Search In this Thesis
   Search In this Thesis  
العنوان
Study of frequency of hepatitis C virus
recurrence in liver transplanted
patients and its response to treatment /
المؤلف
Amer, Mohamed Mohamed Abd-Elatif.
هيئة الاعداد
باحث / محمد محمد عبد اللطيف عاهر
مشرف / عاطف أبو السعود على
مناقش / حسام إبراهيم محمد
مناقش / ايمن محمد اللحلح
الموضوع
Chronic Disease. Hepatitis C - physiopathology.
تاريخ النشر
2018.
عدد الصفحات
202 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الطب (متفرقات)
الناشر
تاريخ الإجازة
8/2/2018
مكان الإجازة
جامعة المنوفية - كلية الطب - طب المناطق الحارة
الفهرس
Only 14 pages are availabe for public view

from 214

from 214

Abstract

Recurrent HCV infection after liver transplantation (LT) is the most
frequent cause of death and represents two-thirds of graft failures and associated
with significant morbidity.
This study was a descriptive retrospective study aimed to estimate the
frequency of recurrent HCV disease after LT and its response to different
treatments regimens and was conducted on 124 chronic HCV liver transplanted
patients with positive serum HCV RNA by PCR technique following LT.
Patients were selected from the International Medical Center (IMC), Cairo,
Egypt during the period from September 2005 till January 2016.
The studied patients were classified into two groups based on the
approved treatment protocols of HCV therapy following LT (Interferon based
therapy from September 2005 till January 2014 Vs DAA based therapy from
January 2014 till January 2016):
GI: Included 106 patients who were underwent LT before January 2014.
According to the histopathological interpretation of liver biopsy following LT,
they were sub classified into two subgroups;G IA[included 41 liver transplanted
patients with histopathological evidence of recurrent HCV disease on liver
biopsy. They were 32 males (78%) and 9 females (22%), their ages ranged from
45 year to 58 years with the mean age of 49.8±4.6 years. These patients were
candidate for interferon based therapy] and G IB [included 65 liver
transplanted patients without histopathological evidence of recurrent HCV
disease on liver biopsy. They were 52 males (80%) and 13 females (20%), their
ages ranged from 42 year to 59 years with the mean age of 50.0±5.6years. These
patients received DAA after their approval]. G II: Included18 patients who
were underwent LT from January 2014 till January 2016 and they were
candidate for DAA therapy based on recurrent HCV viremia following LT.
They were 14 males (77.8%) and 4 females (22.2%), their ages ranged
from 51 year to 62 years with the mean age of 54.8±4.6 years.